 TopNews United States | Novartis' heart failure drug faces hurdles despite upbeat PhIII results FierceBiotech Novartis has detailed the hits and misses from a late-stage trial of its potential blockbuster therapy for acute heart failure, serelaxin, calling the study an overall success and making executives of the Swiss drug giant confident in their plans to ... Serelaxin: Acute Heart Failure Drug Reduces Deaths By 37%, Study Shows RELAX-AHF: Serelaxin reduces dyspnea, but questions surround mortality benefit Pregnancy Hormone May Have Role in HF |
